Hiddo L Heerspink, Niels Jongs, Brendon Neuen, Patrick Schloemer, Muthiah Vaduganathan, Lesley Inker, Robert A Fletcher, David C Wheeler, George Bakris, Tom Greene, Glenn M Chertow, Vlado Perkovic
Doubling of serum creatinine (equivalent to a 57% decline in the estimated glomerular filtration rate (eGFR)) is an accepted component of a composite kidney endpoint in clinical trials. Smaller declines in eGFR (40%, 50%) have been applied in several recently conducted clinical trials. Here, we assessed the effects of newer kidney protective agents on endpoints including smaller proportional declines in eGFR to compare relative event rates and the magnitude of observed treatment effects. We performed a post hoc analysis of 4401 patients in the CREDENCE, 4304 in the DAPA-CKD, 5734 in the FIDELIO-DKD, and 3668 in the SONAR trials, which assessed the effects of canagliflozin, dapagliflozin, finerenone and atrasentan in patients with chronic kidney disease...
April 28, 2023: Kidney International